Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multi-Center, International Study to Investigate Drug-Drug Interactions Between AT2220 and Alglucosidase Alfa in Patients With Pompe Disease

NCT01380743 is registered in ClinicalTrials.gov with Amicus Therapeutics as lead sponsor.

NCT NCT01380743
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01380743 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multi-Center, International Study to Investigate Drug-Drug Interactions Between AT2220 and Alglucosidase Alfa in Patients With Pompe Disease
Lead sponsor
Amicus Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2011
Completion date
January 4, 2013
Enrollment
25 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

pompe disease